Clinical Trials
12 trialsNCT05108298 2026-05-07
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Phase NA Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05544019 2026-02-13
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
Phase 1 Recruiting
NCT05583149 2026-01-29
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06830031 2025-06-13
C402
Shanghai Exuma Biotechnology Ltd.
Phase 1 Recruiting
NCT07012447 2025-06-10
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT02924402 2024-11-13
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
Phase 1 Completed
NCT03434262 2024-05-31
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT05328102 2024-04-30
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
Phase 2 Terminated
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT04476459 2021-03-15
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sun Yat-sen University
Phase 1/2 Unknown